Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.

ABSTRACT: The introduction of serum Prostate Specific Antigen (PSA) testing nearly 30 years ago has been associated with a significant shift towards localized disease and decreased deaths due to prostate cancer. Recognition that PSA testing has caused over diagnosis and over treatment of prostate cancer has generated considerable controversy over its value, and has spurred efforts to identify prognostic biomarkers to distinguish patients who need treatment from those that can be observed. Recent studies show that cancer is heterogeneous and forms a hierarchy of tumor cell populations. We developed a method of identifying prostate cancer differentiation states related to androgen signaling using Boolean logic. Using gene expression data, we identified two markers, CD38 and ARG2, that group prostate c

SUBMITTER: Sahoo D 

PROVIDER: S-EPMC5814231 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature